Transforming Traditional Chinese Medicine (TCM) To Main Stream Pharmaceuticals

Yun K. Tam, Ph.D.
President & CSO of Sinoveda Canada Inc.

Despite TCM has a long history of use and its efficacy has been well documented, its acceptance in the world of mainstream pharmaceuticals is less than desirable. The heart of the problem is quality and reproducibility. Numerous attempts have been experimented to address this issue and some are put into practice; they range from GAP, genetic identification, proprietary extraction, chemical profiling, to name a few, in the past decades. Quality control criteria established using these methodologies often fail to achieve the Chemistry Manufacturing Control (CMC) requirements established for pharmaceuticals. The main issue is that the active components of botanicals are not well characterized. Interactions among these components, their drug-like properties, and dosages are often unknown. These are the fundamental obstacles in the development of botanical pharmaceuticals. In Sinoveda, we have invented a process, Pharmaceutical Platform Technology (PPT®), to identify active ingredients, which are responsible for the clinical activities of botanicals. Products produced using this technology have the features of a pharmaceutical, known active ingredients with defined dosages. In this presentation, the concept of PPT® will be introduced with examples.